Artwork

المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !

🧬 Doug Drysdale - Cybin - Part 2 | Deals Only Get Done in Person | Learning Financing Through a Company’s Hardship | Bureaucracy in the Workplace | How to Educate Yourself to Determine Good Licensing Deals

31:29
 
مشاركة
 

Manage episode 436847794 series 3461709
المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Part 2 of 4.

My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Doug is an experienced investor, Corporate Director, and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents, and raised and invested around $4 billion of public and private capital.

Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. Doug’s extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.

Join us this week and hear about:
  • Doug’s experience in business development
  • His move from crunching numbers to leading deals
  • The challenges of global BD strategies
  • Doug’s move from the UK to San Diego
  • His intricacies of licensing and acquisitions in the pharma industry, and his experiences with Elan, Alpharma, and Actavis

Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:48 Episode starts, Doug defines business development and how a scientist can break into BD
04:21 Global vs. Regional BD, Immersing in travels 3 months at a time, Moving to the US
08:09 Memorable deals at Elan, getting a crash course in financing while going through a layoff period
14:34 Determining when to move on from Elan and start Alkensa
18:33 Next journey after Alkensa to Forest Laboratories, Doug's first experience of bureaucracy in the workplace
22:31 Moving from big pharma to generics at Alpharma, becoming head of M&A
27:28 Doug's advice on identifying what you want to license and what makes for a good licensing deal, fundraising types at Alpharma
29:15 Sell side vs. acquisition side
30:23 Outro

Find Our Guest, Doug Drysdale, at these links:

Find Our Host, Jon Chee, at these links:

Social & Website
Enriched Notes:

Topics Mentioned:
How to Fund an R&D Startup: First Steps a Founder Can Take https://www.excedr.com/resources/rd-startup-funding-first-steps
Biotech Funding for Startups: What Are Your Options? https://www.excedr.com/resources/biotech-startup-funding-options
Equipment Leasing vs. Financing: What's the Difference? https://www.excedr.com/blog/equipment-leasing-vs-financing
Top VC Firms for Biotech in 2024: Supporting Innovation & Growth https://www.excedr.com/blog/top-vc-firms-for-biotech
VC Term Sheets: Definition, Key Components & More https://www.excedr.com/resources/venture-capital-term-sheets
What Is Series A, B, & C Funding? Series Funding Explained https://www.excedr.com/resources/series-funding-explained
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

92 حلقات

Artwork
iconمشاركة
 
Manage episode 436847794 series 3461709
المحتوى المقدم من Jon Chee. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Jon Chee أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Part 2 of 4.

My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Doug is an experienced investor, Corporate Director, and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents, and raised and invested around $4 billion of public and private capital.

Before Cybin, Doug was Commercial Products Manager at DuPont Merck, Director of BD at Elan, VP of M&A at Actavis Group, CEO of Norwich Pharmaceuticals and Alvogen, CEO of Pernix Therapeutics, and CEO of Tedor Pharma. Doug’s extensive background as a seasoned executive, investor, and turn-around specialist gives him a wide range of experiences that founders can learn from.

Join us this week and hear about:
  • Doug’s experience in business development
  • His move from crunching numbers to leading deals
  • The challenges of global BD strategies
  • Doug’s move from the UK to San Diego
  • His intricacies of licensing and acquisitions in the pharma industry, and his experiences with Elan, Alpharma, and Actavis

Please enjoy my conversation with Doug Drysdale.
Timestamps:
00:28 Intro
01:48 Episode starts, Doug defines business development and how a scientist can break into BD
04:21 Global vs. Regional BD, Immersing in travels 3 months at a time, Moving to the US
08:09 Memorable deals at Elan, getting a crash course in financing while going through a layoff period
14:34 Determining when to move on from Elan and start Alkensa
18:33 Next journey after Alkensa to Forest Laboratories, Doug's first experience of bureaucracy in the workplace
22:31 Moving from big pharma to generics at Alpharma, becoming head of M&A
27:28 Doug's advice on identifying what you want to license and what makes for a good licensing deal, fundraising types at Alpharma
29:15 Sell side vs. acquisition side
30:23 Outro

Find Our Guest, Doug Drysdale, at these links:

Find Our Host, Jon Chee, at these links:

Social & Website
Enriched Notes:

Topics Mentioned:
How to Fund an R&D Startup: First Steps a Founder Can Take https://www.excedr.com/resources/rd-startup-funding-first-steps
Biotech Funding for Startups: What Are Your Options? https://www.excedr.com/resources/biotech-startup-funding-options
Equipment Leasing vs. Financing: What's the Difference? https://www.excedr.com/blog/equipment-leasing-vs-financing
Top VC Firms for Biotech in 2024: Supporting Innovation & Growth https://www.excedr.com/blog/top-vc-firms-for-biotech
VC Term Sheets: Definition, Key Components & More https://www.excedr.com/resources/venture-capital-term-sheets
What Is Series A, B, & C Funding? Series Funding Explained https://www.excedr.com/resources/series-funding-explained
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

92 حلقات

كل الحلقات

×
 
Loading …

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

 

دليل مرجعي سريع